Dashboard
Manage Tickers

VTGN


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

vistagen-therapeutics-cfo-cynthia-l-anderson-resigns-effective-october-15-2025
Vistagen Therapeutics' CFO Cynthia L. Ande...
09/15/2025 20:56:22

-SEC Filing

vistagen-therapeutics-q1-eps-047-beats-050-estimate-sales-24400k-miss-65000k-estimate
VistaGen Therapeutics Q1 EPS $(0.47) Beats...
08/07/2025 20:51:27

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

insights-ahead-vistagen-therapeuticss-quarterly-earnings
Insights Ahead: VistaGen Therapeutics's Qu...
08/06/2025 21:02:11

vistagen-therapeutics-files-for-offering-of-up-to-175m-of-common-stock
Vistagen Therapeutics Files For Offering O...
06/17/2025 20:53:32

-SEC Filing

vistagen-therapeutics-q4-eps-044-beats-050-estimate-sales-1500k
VistaGen Therapeutics Q4 EPS $(0.44) Beats...
06/17/2025 20:41:43

Core News & Articles
Earnings Scheduled For June 17, 2025
06/17/2025 08:32:11

insights-into-vistagen-therapeuticss-upcoming-earnings
Insights into VistaGen Therapeutics's Upco...
06/16/2025 14:02:10

vistagen-therapeutics-provides-update-for-us-registration-directed-palisade-3-phase-3-trial-evaluating-fasedienol-for-acute-treatment-of-social-anxiety-disorder
Vistagen Therapeutics Provides Update For ...
06/02/2025 12:34:24

Company's PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026

vistagen-therapeutics-q3-eps-046-beats-051-estimate-sales-23400k-beat-18000k-estimate
VistaGen Therapeutics Q3 EPS $(0.46) Beats...
02/13/2025 21:42:19

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of...

earnings-scheduled-for-february-13-2025
Earnings Scheduled For February 13, 2025
02/13/2025 08:32:25

vistagen-granted-us-patent-for-av-101-to-treat-neuropathic-pain
Vistagen Granted US Patent For AV-101 To T...
02/05/2025 13:35:27

vistagen-announces-uspto-patent-grant-for-av-101-oral-non-opioid-neuropathic-pain-treatment-expiring-2034
Vistagen Announces USPTO Patent Grant For ...
02/05/2025 13:35:02

vistagen-announces-results-from-exploratory-phase-2a-study-of-ph284-in-cancer-cachexia-ph284-nasal-spray-demonstrated-improvements-to-subjective-feelings-of-hunger-in-cancer-patients
Vistagen Announces Results From Explorator...
01/14/2025 13:32:19

PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patientsPH284 is the fifth pherine produ...

vistagen-announces-phase-3-program-for-social-anxiety-disorder-with-fasedienol-first-enrollment-in-us-study-for-efficacy-safety-tolerability-during-public-speaking-challenge
Vistagen Announces Phase 3 Program For Soc...
01/10/2025 13:37:27

All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety...

vistagen-therapeutics-q2-2025-gaap-eps-042-misses-039-estimate-sales-183000k-miss-223333k-estimate
VistaGen Therapeutics Q2 2025 GAAP EPS $(0...
11/08/2024 00:08:04

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate ...

vistagen-initiates-palisade-4-phase-3-study-of-fasedienol-for-acute-treatment-of-social-anxiety-disorder
Vistagen Initiates PALISADE-4 Phase 3 Stud...
09/23/2024 12:32:12

vistagen-therapeutics-q1-2025-adj-eps-035-beats-041-estimate-sales-8400k-miss-30000k-estimate
VistaGen Therapeutics Q1 2025 Adj EPS $(0....
08/13/2024 20:23:27

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of...

vistagen-expands-global-intellectual-property-portfolio-with-new-patents-for-ph80-nasal-spray-investigational-treatment-for-migraine-hot-flashes-due-to-menopause-premenstrual-dysphoric-disorder-and-dysmenorrhea
Vistagen Expands Global Intellectual Prope...
07/09/2024 12:34:27

vistagen-reports-fy24-net-loss-of-294m-vs--592m-last-year
Vistagen Reports FY24 Net Loss Of $(29.4)M...
06/11/2024 20:23:05

Cash and cash equivalents were $119.2 million as of March 31, 2024.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION